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Introduction: Fluorescence in situ hybridization (FISH) is the stan-
dard procedure for the detection of anaplastic lymphoma receptor 
tyrosine kinase (ALK) rearrangement in non–small-cell lung carci-
noma (NSCLC) but is expensive and time consuming. We tested three 
antibodies to ALK, using various detection systems, and hypothesized 
that ALK immunohistochemistry (IHC) may represent a cost-effective 
and efficient means of screening for ALK rearrangement in NSCLC.
Methods: We screened 377 stage I or II NSCLC cases in a tissue 
microarray by FISH and IHC (5A4 [Leica Biosystems Newcastle Ltd, 
Newcastle upon Tyne, UYnited Kingdom] by Nichirei’s N-Histofine 
ALK detection kit [Nichirei Biosciences inc., Tokyo, Japan], 5A4 by 
Novocastra with ADVANCE [Dako Canada inc., Burlington, Ontario, 
Canada], D5F3 by Cell Signaling Technology with ADVANCE [Cell 
Signalling Technologies inc., Danvers, MA], and DAKO clone ALK1 
with FLEX [Dako Canada inc., Burlington, Ontario, Canada] and 
ADVANCE). IHC was scored as 0, 1+, 2+, or 3+. Possibly positive 
or positive cases were further analyzed by IHC and FISH on whole 
section.
Results: Tissue microarray results were available on 377 cases by 
IHC and 273 cases by FISH. Eleven cases were positive or possi-
bly positive by either IHC or FISH, and three cases were positive or 
 possibly positive by both methods. Three cases were ALK-positive by 
FISH on whole section validation. There was no correlation between 
semiquantitative IHC score (1+, 2+, 3+) and ALK rearrangement by 
FISH. D5F3 (Cell Signaling by ADVANCE) and 5A4 (Novocastra 
by ADVANCE) showed the greatest combination of sensitivity 
(100%) and specificity (87.5% for 5A4 by Novocastra and 75% for 
D5F3 by Cell Signaling), and produced no false- negative results.
Conclusions: IHC is a reliable screening tool for identification of 
ALK rearrangement in NSCLC and is antibody dependent. D5F3 
(Cell Signaling) and 5A4 (Novocastra) can be used with FISH for 
identification of IHC-positive cases to reduce screening costs.
Key Words: Immunohistochemistry, Fluorescence in situ hybridiza-
tion, Anaplastic lymphoma receptor tyrosine kinase rearrangement, 
Non–small-cell lung carcinoma.
(J Thorac Oncol. 2013;8: 45–51)
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite continued improvements in diagnosis 
and therapy,1,2 the prognosis of lung cancer remains remarkably 
poor. Only 15% of patients present with localized disease that 
is amenable to resection.3 Of the various types of lung cancer, 
non–small-cell lung carcinoma (NSCLC) accounts for approx-
imately 80% of cases and many NSCLC patients are diagnosed 
at an advanced stage.4 Conventional chemotherapy and radio-
therapy have significant morbid side effects and only margin-
ally improve the outcome of these patients, with their median 
survival time being less than 1 year after diagnosis.4 The identi-
fication of activating mutations in the epidermal growth factor 
receptor (EGFR) in a subset of lung cancers was a tremendous 
breakthrough in lung cancer research and therapy.5,6
Recently, activation of the anaplastic lymphoma 
receptor tyrosine kinase gene (ALK) in NSCLCs by fusion 
with the echinoderm microtubule-associated protein-like 
4 (EML4) gene was identified.4 ALK rearrangements occur 
in approximately 2% to 13% NSCLCs, depending on the 
population studied,7–11 and are mutually exclusive of EGFR 
and KRAS mutations.3 Most ALK-positive lung cancers are 
adenocarcinomas, with certain histological subtypes being 
more common, including signet-ring structure.12 ALK-positive 
lung carcinomas tend to occur in younger patients, with the 
mean age of onset being mid-50s.13 In addition, most patients 
are never or light smokers (< 10 pack/year), and there is no 
consistent association with a specific sex.13,14
Interest in ALK-positive NSCLC has peaked after clinical 
trials with crizotinib, a drug originally developed as an inhibi-
tor of MET, but later shown to inhibit ALK also. Clinical trials 
have shown that patients with ALK-positive NSCLC have dra-
matic, rapid response rates, with tumor size shrinkage or sta-
bilization.15,16 One study showed an objective response rate of 
57% and disease control rate of 87% at 8 weeks,17 with tumor 
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shrinkage rates approaching 50% in one patient.16 The overall 
mean progression-free survival for ALK-positive lung carcinoma 
is estimated to be similar to EGFR targeted therapy (approxi-
mately 10 months) with relatively mild and tolerable side 
effects.18–20 Although drug resistance eventually develops,21 the 
improved quality of life is significant. Recently, these favorable 
results have led to crizotinib gaining approval for the treatment 
of advanced stage ALK-positive NSCLC in Japan, the United 
States, Canada, and several other countries in Europe and Asia.
The identification of an effective therapy for ALK-positive 
NSCLC places great emphasis on rapid, accurate, and cost-
effective identification of patients with this subtype of lung 
cancer. Fluorescence in situ hybridization (FISH) is the current 
standard method to detect ALK rearrangement and the only test 
correlated with clinical response because of its use in clinical tri-
als. However, FISH is not readily available as a routine method 
of pathology practice in most laboratories because it is time 
consuming and requires advanced technical and professional 
expertise. In contrast, immunohistochemistry (IHC) is relatively 
inexpensive, faster, and is perfectly adapted for routine practice 
by academics and most community hospitals. Given the high 
incidence of lung carcinoma, a large volume of cases requires 
rapid screening for the identification of those few NSCLC 
patients who may benefit from ALK inhibitors. Therefore, the 
validation of ALK IHC as a screening test is essential and timely.
This article is one of the first to semiquantitatively 
evaluate various commercially available ALK antibodies in 
a cohort of NSCLC patients, using FISH as the standard 
procedure. We hypothesized that IHC can be used to screen 
for ALK-positive NSCLC, with confirmatory FISH based on 
IHC scoring, a system well established in human epidermal 
growth factor receptor-2 (HER2) screening in patients with 
breast cancer.
PATIENTS AND METHODS
Patients and Samples
The study included 377 cases of early stage (I or II) 
NSCLC, diagnosed between 1978 and 2002, and retrieved 
from St. Paul’s Hospital, in Vancouver, British Columbia. 
The cohort consisted of 178 squamous cell carcinomas, 145 
adenocarcinomas, 26 large cell carcinomas, 20 poorly dif-
ferentiated non–small-cell carcinomas, four adenosquamous 
carcinomas, three carcinosarcomas, and one large-cell neu-
roendocrine carcinoma. Other than resectable lung cancer, 
no other specific selection criteria were used. The cases were 
formalin-fixed and paraffin embedded (FFPE). Duplicate 
0.6-mm tissue cores were used in the construction of the tis-
sue microarray, as previously described.22 All cases were inde-
pendently screened for ALK rearrangement by FISH, and for 
ALK expression by three available antibodies to ALK with 
various detection systems. Cases identified as either possibly 
positive or positive for ALK rearrangement by either FISH or 
IHC were further tested, using the whole section (WS) FFPE 
tissue, and subjected to IHC and FISH by the same methods. 
This study was approved by the Toronto University Health 
Network (11-0537-T) and the University of British Columbia 
Bioethical Committees.
Immunohistochemistry for ALK Expression
FFPE tissues were sectioned at a thickness of 4µm and 
stained with three different antibodies to ALK using vari-
ous detection systems (5A4 by Nichirei’s N-Histofine ALK 
detection kit [Tokyo, Japan], 5A4 by Novocastra [Newcastle, 
United Kingdom] with ADVANCE detection, D5F3 by Cell 
Signaling Technology [Billerica, MA] by ADVANCE detec-
tion, and DAKO clone ALK1 [Carpenteria, CA] by FLEX and 
ADVANCE detection). Staining and detection was performed 
according to each manufacturer’s instructions. Specifically, 
for the ADVANCE detection system, slides were placed on the 
Dako Autostainer (Dako); primary antibody (mouse monoclo-
nal ALK antibody, clone ALK1; Dako; 1:100 dilution) was 
applied and incubated for 30 minutes. Antigen–antibody reac-
tion was visualized by an enhanced polymer-based detection 
system, ADVANCE (Dako), with 30-minute incubation for 
ADVANCE link and 30-minute incubation for ADVANCE 
horseradish peroxidase. Diaminobenzidene (DAB) was 
employed for 5 minutes as the chromogen. Flex detec-
tion systems uses the Envision FLEX blocking agent and 
Envision FLEX HRP, with identical times of incubation as the 
ADVANCE system.
ALK expression was assessed by two pathologists 
without knowledge of the results obtained by FISH or the 
clinicopathologic information. Semiquantitative assessment 
was performed by estimating the intensity of cells with 
cytoplasmic staining, according to the following criteria: 3+, 
intense, granular cytoplasmic staining; 2+, moderate, smooth 
cytoplasmic staining; 1+, faint cytoplasmic staining in any 
tumor cells; and 0/negative, no staining (Fig. 1). IHC score 3+ 
cases showed widespread, although sometimes patchy, easily 
discernible intense cytoplasmic positivity with a distinct 
granular texture (Fig. 1A). IHC score 2+ cases also showed 
readily recognizable positivity but to a lesser extent, and with 
less staining intensity than score 3+ cases. In general, 2+ cases 
lacked the granular texture of 3+ cases, and instead, showed 
more smooth cytoplasmic staining (Fig. 1B). IHC score 1+ 
cases showed only faintly smudged cytoplasmic staining (Fig. 
1C). Typically, the observer struggled to determine whether 
the faint positivity of score 1+ represented a background stain 
or real positivity, unlike the readily detectable staining of 
score 2+ and 3+. IHC score 0 cases showed a complete lack 
of staining (Fig. 1D). Consensus was established by reviewing 
the slides together. In discrepant cases, a third pathologist 
acted as the arbitrator. IHC possibly positive cases were 1+ 
and 2+. IHC positive and negative cases were 3+ and 0 only, 
respectively.
Fluorescence In Situ Hybridization 
for ALK Rearrangement
FISH was performed on unstained 4-µm FFPE tis-
sue sections using a commercially available ALK break-
apart probe (Vysis LSI ALK Dual Color, Break Apart 
Rearrangement Probe; Abbott Molecular, Abbott Park, IL). 
Slides were mounted in VECTASHIELD mounting medium 
(Vector Laboratories, Burlingame, CA) with 1.5 ug/ml of 4ʹ 
6-diamidino-2-phenylindole.
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The ALK break-apart probe set includes a 250-kb DNA 
fragment telomeric to ALK (3ʹ end) labeled in Spectrum 
Orange (red fluorophore), and a 300-kb DNA fragment cen-
tromeric to ALK (5ʹ end) labeled in Spectrum Green (green 
fluorophore). Nonrearranged ALK showed fusion (yellow sig-
nals) or very close apposition of the probes adjacent to the 3ʹ 
(red) and the 5ʹ (green) ends of the gene. Rearranged ALK 
appeared as split 3ʹ (solitary red) signal and 5ʹ (solitary green) 
signal. Three observers (1 pathologist and 2 trained technolo-
gists), blinded to the IHC and the clinicopathologic informa-
tion, screened TMAs that had been hybridized for ALK. A 
possibly positive case by FISH was defined as at least five 
cells with break-apart and/or solitary red or green signals 
identified after 15 to 30 seconds evaluation. All possibly posi-
tive or positive TMA cases were reevaluated using WS FFPE 
tissue and scored by two observers to reach a final consensus 
of whether positive or negative. Signals were evaluated in 100 
cells by each observer. Tumor tissues were considered ALK-
positive by FISH if 20% or more cells showed break-apart 
(solitary red signals and/or red and green signals > 1-signal 
width apart [Fig. 2]). Samples that did not meet these criteria 
were considered ALK-FISH negative.
RESULTS
TMA results were available on all 377 cases by IHC 
and 273 cases by FISH. FISH screening results could not be 
obtained on 104 FISH cases mostly because of high fluorescent 
background, which in most cases is thought to be caused by 
prolonged fixation time before embedding. A smaller subset of 
cases had poor signal quality for unknown reasons, or absence 
of carcinoma cells in the cores. Eleven cases were positive or 
possibly positive by either IHC or FISH (Table 1). Six of the 
cases showed ALK protein expression by any of the antibody 
systems, and eight cases were at least possibly positive for ALK 
rearrangement by FISH. Three cases were either positive or 
possibly positive by both methods (cases 3, 7, and 11).
As a validation set, we reexamined the WS FFPE sur-
gically resected specimens corresponding to the possibly 
positive or positive cases identified by TMA screening. Three 
A B
C D
FIGURE 1.  Semiquantitative immunohistochemical staining using an antibody to ALK (D5F3 by Cell Signaling [Billerica, MA] 
with ADVANCE detection), 400x original magnification. A, IHC score 3+ showing intense granular cytoplasmic staining. B, IHC 
score 2+ showing moderate smooth cytoplasmic staining (without granularity seen in score 3+). C, IHC score 1+ showing faint, 
barely discernible cytoplasmic staining in any tumor cells. D, IHC score 0/negative showing no staining. ALK, anaplastic lym-
phoma receptor tyrosine kinase; IHC, immunohistochemistry
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cases were confirmed positive for ALK rearrangement by 
FISH (cases 3, 7, and 11), making the incidence of ALK rear-
rangement in our cohort 1.1%. Two of the three ALK-positive 
FISH cases showed classic break-apart signals (cases 7 and 
11). One case showed solitary red signals (3ʹ ALK signals), 
which is seen in a subset of ALK-rearranged lung cancers 
(case 3).23–25 All these three cases were also positive or pos-
sibly positive for ALK rearrangement by FISH and IHC on 
TMA screening (Table 1).
There was no correlation between the semiquantitative 
IHC score (1+, 2+, or 3+) and the three ALK-positive cases by 
FISH. One each of the ALK-positive FISH cases was scored 
1+, 2+, and 3+ by IHC by several antibody and detection sys-
tems. ALK1 by DAKO with FLEX detection produced the 
only false-negative result (Table 2). One case showed intratu-
moral herterogeneity, characterized by 3+ and negative stain-
ing with ALK IHC (case 4). In addition, 1+ or 2+ staining of 
the plasma cells and macrophages was noted.
The sensitivity and specificity of the various antibody 
detection systems, including any ALK-expression by IHC 
on TMA or WS (1+, 2+, or 3+), using FISH on the valida-
tion set as the standard procedure, were as follows: D5F3 
(by Cell Signaling with ADVANCE detection) and 5A4 (by 
Novocastra with ADVANCE, and by Nichirei) both showed 
100% sensitivity compared with DAKO clone ALK1 (with 
both ADVANCE and FLEX detection), which showed 66% 
sensitivity. Of the most sensitive antibody systems, 5A4 by 
Novocastra and D5F3 by Cell Signaling showed 87.5% and 
75% specificity, respectively. Comparatively, 5A4 by Nichirei 
showed 62.5% specificity (Table 3). Overall, D5F3 (by Cell 
Signaling with ADVANCE detection) and 5A4 (by Novocastra 
with ADVANCE detection) showed the greatest combination 
of sensitivity and specificity. These two antibody systems also 
showed identical IHC scores on TMA and validation testing, 
suggesting that they may represent the most consistent and 
reliable ALK antibodies for NSCLC screening. Furthermore, 
there were only two false-positive cases by these two antibody 
systems (cases 2 and 4).
Correlation with the clinicopathologic information 
showed that all three ALK-positive cases by FISH were 
diagnosed as adenocarcinomas. The patients were relatively 
young: all patients were 56 years of age or less, at the time of 
diagnosis. There was no correlation between sex or smoking 
history and ALK positivity. Two of the three ALK-positive 
cases were women. One patient was a nonsmoker, and one 
had a smoking history of 50 pack-years (Table 4).
DISCUSSION
FISH analysis is the current standard procedure for the 
selection of patients suitable for crizotinib therapy. However, 
FISH is expensive, time consuming, and is not universally 
available.26 Furthermore, the incidence of ALK rearrangement 
FIGURE 2.  Dual-color break-apart FISH performed using the 
commercially available ALK probe (Vysis LSI ALK Dual Color, 
Break Apart Rearrangement Probe, Abbott Molecular, Abbott, 
IL) on case 11. ALK break-apart FISH showed a straightfor-
ward break-apart signal configuration (1 red, 1 green, 1 
fusion [1R1G1F]) in 51% of the nuclei, indicating ALK rear-
rangement. Splitting of the red and green signals (shown 
with arrows) indicates ALK rearrangement. ALK, anaplastic 
lymphoma receptor tyrosine kinase; NSCLC, non–small-cell 
lung carcinoma; FISH, fluorescence in situ hybridization.
TABLE 1. ALK-Positive or Possibly Positive Cases by IHC and/or FISH on TMA Screening
Case Number
5A4 by Nichirei 
with Histofine
ALK1 by DAKO 
with FLEX
ALK1 by DAKO 
with Advance
5A4 by Novocastra with 
Advance
D5F3 by Cell Signaling 
with Advance
FISH TMA 
Screening Results
1 0 0 0 0 0 Possibly positive
2 1+ 0 0 0 1+ Negative
3 2+ 0 0 2+ 2+ Possibly positive
4 1+ 0 0 0 and 2+ (heterogeneity) 0 and 3+ (heterogeneity) Negative
5 0 0 0 0 0 Possibly positive
6 0 0 0 0 0 Possibly positive
7 3+ 2+ 2+ 3+ 3+ Positive
8 0 0 0 0 0 Possibly positive
9 0 0 0 0 0 Possibly positive
10 2+ 0 0 0 0 Negative
11 0 0 0 1+ 1+ Possibly positive
Eleven cases identified as either ALK positive or possibly positive by IHC and/or FISH based on TMA screening. Three cases (cases 3, 7, 11) were possibly positive or positive 
for ALK rearrangement by both IHC and FISH.
ALK, anaplastic lymphoma receptor tyrosine kinase; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; TMA, tissue microarray.
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in NSCLC is relatively rare and there is increased incentive 
to develop a cost-effective and efficient screening algorithm, 
such as IHC, which can be integrated seamlessly into daily 
pathology practice. We therefore performed this study to 
evaluate the potential role of IHC as a detection or screen-
ing method for ALK rearrangement in NSCLC. Whereas most 
studies evaluating detection of ALK rearrangement in NSCLC 
have either performed FISH only on IHC-positive cases or 
IHC on FISH-positive cases, which precludes accurate assess-
ment of sensitivity and specificity, in this study, all cases were 
independently screened by FISH and IHC.
On the basis of our cohort of 377 low-stage NSCLC 
cases, we had IHC results on all the cases and FISH results 
on 273 cases. Eleven cases were either possibly positive or 
positive for ALK rearrangement by either method (6 by IHC 
and 8 by FISH) and subjected to validation testing using the 
corresponding surgically resected specimens. Three cases 
were confirmed ALK-positive by FISH, indicating that the 
incidence of ALK-positivity in our cohort was 1.1%. This 
incidence is lower than the 2% to 13% reported in other stud-
ies.7–11 However, studies that report greater incidence of ALK 
rearrangement often employ an ALK-enriched population by 
selecting advanced-stage NSCLC cases with adenocarcinoma 
histology and excluding patients with smoking histories and 
tumors with EGFR and KRAS mutations.
We found that all cases exhibiting ALK rearrangement 
demonstrated adenocarcinoma histology. Furthermore, all 
ALK-positive patients were relatively young (< 60 years of 
age) at the time of diagnosis. These findings are consistent 
with previous reports in which most ALK-positive NSCLC 
were adenocarcinomas, and occurred in young patients. 
However, unlike past reports, which have shown an associa-
tion with sex and never- to light smokers, this study shows no 
association between ALK rearrangement and sex or smoking. 
We realize that the relatively small number of ALK rearranged 
TABLE 2.  Results from the Validation Set Using FISH as the Standard Procedure
Case Number
5A4 by Nichirei 
with Histofine
ALK1 by DAKO 
with FLEX
ALK1 by DAKO 
with ADVANCE
5A4 by Novocastra  
with ADVANCE
D5F3 by Cell Signaling  
with ADVANCE
FISH Results 
on WS
1 0 0 0 0 0 Negative
2 1+ focal 0 0 0 1+ Negative
3 2+ diffuse 1+ 2+ 2+ 2+ Positive
4 3+ focal 0 0 0 and 2+ (heterogenetity) 0 and 3+ (heterogeneity) Negative
5 0 0 0 0 0 Negative
6 0 0 0 0 0 Negative
7 3+ diffuse 2+ 2+ 3+ 3+ Positive
8 0 0 0 0 0 Negative
9 0 0 0 0 0 Failed
10 0 0 0 0 0 Negative
11 2+ diffuse 0 1+ 1+ 1+ Positive
Three cases were identified as ALK positive (cases 3, 7, 11). There was no correlation between the semiquantitative immunohistochemistry score (1+, 2+, or 3+) and ALK-
positivity by FISH. There was one false-negative case (case 11) with ALK1 by DAKO with FLEX detection.
Bold indicates ALK-positive cases by FISH.
FISH, fluorescence in situ hybridization; ALK, anaplastic lymphoma receptor tyrosine kinase; WS, whole section tissue.
TABLE 3.  Sensitivity and Specificity of the Various 
Commercially Available ALK Antibodies and Detection Systems
Antibody System Sensitivity % Specificity %
5A4 by Novocastra with ADVANCE 100 87.5
D5F3 by Cell Signaling with ADVANCE 100 75
5A4 by Nichirei with Histofine 100 62.5
ALK1 by DAKO with FLEX 66 100
ALK1 by DAKO with ADVANCE 66 87.5
5A4 by Novocastra and D5F3 by Cell Signaling with ADVANCE detection 
showed the greatest combination of sensitivity and specificity as a screening tool, using 
fluorescence in situ hybridization
as the standard procedure. ALK, anaplastic lymphoma receptor tyrosine kinase.
TABLE 4.  Correlation between Clinicopathologic 
Information and ALK Rearrangement in this NSCLC Cohort
Case  
Number
Age  
(Years) Sex
Smoking  
(Pack-Years) Diagnosis
1 52 Male N/A SQC
2 74 Male 88.5 SQC
3 56 Female 0 ACA
4 77 Female 27.5 ACA
5 49 Female 16 ACA
6 67 Male n/a SQC
7 54 Female 8.4 ACA
8 61 Female 18 NSCLC, NOS
9 67 Male 100 SQC
10 76 Male 31.5 SQC
11 48 Male 50 ACA
All ALK-positive cases were adenocarcinomas and were diagnosed in patients at a 
relatively young age (< 60 yr old). There was no correlation between sex and smoking 
and ALK positivity in this cohort.
Bold indicates ALK-positive cases by FISH.
ACA, adenocarcinoma; SQC, squamous cell carcinoma; NSCLC, non–small-cell 
carcinoma; NOS, poorly differentiated non–small-cell carcinoma, of no specific type; 
FISH, fluorescence in situ hybridization.
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cases in our cohort limits the impact of these clinicopathologi-
cal correlations, and that a large-scale meta-analysis would be 
needed to verify these findings.
FISH results on TMA screening were not available on 
all cases. When using FISH as a standard procedure for ALK 
rearrangement, it is important to remember that it has its 
own pitfalls. In addition to those outlined in the Results sec-
tion, interpretation of FISH for ALK-positive NSCLC tends 
to be more difficult than in anaplastic large-cell lymphoma 
or inflammatory myofibroblastic tumor because ALK rear-
rangement with EML4 in NSCLC is an intrachromosomal 
inversion, resulting in a relatively close separation of the 
break-apart probes. Reverse transcription-polymerase chain 
reaction can detect specific abnormal fusion transcripts and 
has been tested as a detection method for ALK rearrangement. 
However, it is also costly, and labor intensive.26 Furthermore, 
reverse transcription-polymerase chain reaction may miss up 
to 30% of true ALK-positive cases because of the difficulty 
in obtaining high-quality DNA postfixation and the inabil-
ity of this method to detect all ALK translocation variants.15 
Therefore, despite, the potential shortcomings of FISH test-
ing, it still remains the current best standard procedure for the 
identification of ALK-positive NSCLC, especially given that it 
is the only method correlated to clinical outcome. It is impor-
tant for laboratories to have in place routine methods regard-
ing ischemic and fixation times for all resected tumours, to 
produce optimal FISH results.
Using FISH as the standard procedure, we conclude that 
IHC may be a reliable screening tool for ALK rearrangement 
but is dependent on the type of antibody and detection system 
used. On the basis of our observations, among the commer-
cially available antibodies to ALK, both 5A4 by Novocastra 
and D5F3 by Cell Signaling, with ADVANCE detection sys-
tems, provided the greatest combination of sensitivity (100%) 
and specificity (87.5% for 5A4 by Novocastra and 75% for 
D5F3 by Cell Signaling). Furthermore, these two antibodies 
produced no false-negative results, and are therefore, the most 
recommended to screen for ALK rearrangement in NSCLC.
These results are in concordance with other studies that 
show that 5A4 and D5F3 by Cell Signaling are highly sensitive 
and specific in predicting ALK rearrangement, using FISH as 
the standard procedure. Recently, Park et al.27 studied an ALK-
enriched cohort of stage III and IV NSCLC cases and found 
that 5A4 by Novocastra produced no false-negatives and was 
100% sensitive and 98.5% specific for detecting ALK rear-
rangement. In addition, Mino-Kenudson et al.24 showed 100% 
sensitivity and 99% specificity for D5F3 by Cell Signaling 
using a cohort of 153 cases of lung adenocarcinoma. Using 
an intercalated antibody-enhanced polymer detection system, 
Takeuchi et al.28 showed that 5A4 by Abcam was 100% sensi-
tive for ALK rearrangement in a cohort of 11 ALK-positive 
lung carcinomas, identified by FISH. In contrast, the results 
with ALK1 clone by DAKO have shown variable sensitivi-
ties ranging from 67% to 100% in cohorts of 40 to 153 ALK-
positive cases by FISH.11,24 These results are in agreement 
with our study, which showed low sensitivity (66%) with 
ALK1 by DAKO with either the ADVANCE or FLEX detec-
tion systems. In addition, this antibody was the most difficult 
to evaluate semiquantitatively in this study as it produced the 
greatest amount of background staining, a finding supported 
by Mino-Kenudson et al.24
Other studies, using ALK1 by DAKO and 5A4 by 
Novocastra, have shown a correlation between semiquantitative 
IHC scoring and ALK positivity by FISH.23,29 In these studies, 
1+ and 3+ IHC scores represented ALK-negative and ALK-
positive cases, respectively, and 2+ cases were equivocal, 
suggesting a similar screening algorithm as exists for HER2 
testing in breast cancer. However, our results indicate that 
among our most sensitive and specific antibodies to ALK, 
D5F3 by Cell Signaling and 5A4 by Novocastra, there was 
no correlation between the degree of IHC staining and the 
FISH results. Specifically, the three ALK-positive cases by 
FISH were scored as either 1+, 2+, or 3+ on validation testing. 
We, therefore, recommend a simple screening algorithm as 
outlined in Figure 3. All NSCLCs could be screened using 
either D5F3 by Cell Signaling or 5A4 by Novocastra with 
ADVANCE detection. Cases with any ALK expression by 
IHC, regardless of the degree, would be tested by FISH for 
confirmation of ALK positivity. Cases with no ALK expression 
by IHC would be considered ALK negative, and would not 
have to be tested by FISH, thereby reducing costs. This 
algorithm uses commercially available IHC and represents 
an inexpensive and convenient screening method, using FISH 
confirmation, to identify ALK-positive NSCLC patients who 
will benefit from ALK-targeted therapy. Further study, perhaps 
involving a larger cohort of ALK-positive NSCLC cases, is 
recommended to confirm our results.
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